256 related articles for article (PubMed ID: 33276639)
1. Efficacy of Dabrafenib Plus Trametinib Combination in Patients with
Auliac JB; Bayle S; Do P; Le Garff G; Roa M; Falchero L; Huchot E; Quéré G; Jeannin G; Métivier AC; Hobeika J; Guisier F; Chouaid C
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33276639
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
3. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
Qu J; Shen Q; Li Y; Kalyani FS; Liu L; Zhou J; Zhou J
Front Oncol; 2022; 12():911303. PubMed ID: 35814395
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis.
Li J; Sasane M; Zhao J; Horton VG; Zhang P; Ricculli ML; Zhou ZY; Signorovitch J
Adv Ther; 2018 Jul; 35(7):1035-1048. PubMed ID: 29949047
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer.
Mu Y; Yang K; Hao X; Wang Y; Wang L; Liu Y; Lin L; Li J; Xing P
Front Oncol; 2020; 10():603. PubMed ID: 32411601
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.
Planchard D; Besse B; Groen HJM; Hashemi SMS; Mazieres J; Kim TM; Quoix E; Souquet PJ; Barlesi F; Baik C; Villaruz LC; Kelly RJ; Zhang S; Tan M; Gasal E; Santarpia L; Johnson BE
J Thorac Oncol; 2022 Jan; 17(1):103-115. PubMed ID: 34455067
[TBL] [Abstract][Full Text] [Related]
10. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
[TBL] [Abstract][Full Text] [Related]
11. Dabrafenib and trametinib administration in patients with
Shimoi T; Sunami K; Tahara M; Nishiwaki S; Tanaka S; Baba E; Kanai M; Kinoshita I; Shirota H; Hayashi H; Nishida N; Kubo T; Mamesaya N; Ando Y; Okita N; Shibata T; Nakamura K; Yamamoto N
EClinicalMedicine; 2024 Mar; 69():102447. PubMed ID: 38333370
[TBL] [Abstract][Full Text] [Related]
12. Dabrafenib plus trametinib in patients with BRAF
Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
[TBL] [Abstract][Full Text] [Related]
13. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring
Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K
Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Real-World Patients with High-Risk
Quaglino P; Ascierto PA; Consoli F; Queirolo P; Spagnolo F; Morelli MF; Berardi R; Chiarion-Sileni V; Tucci M; Troiani T; Melotti B; Rossi E; Mandala M; Rinaldi G; Marcon IG; Pizzuti M; Del Vecchio M
Cancer Manag Res; 2023; 15():1271-1281. PubMed ID: 38027240
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
16. Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma With Small Bowel Metastasis.
Gullapalli K; Mosalem O; Varghese MT; Watat K; Hrinczenko B
Cureus; 2021 Jul; 13(7):e16431. PubMed ID: 34466299
[TBL] [Abstract][Full Text] [Related]
17. Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma.
Amdahl J; Chen L; Delea TE
Oncol Ther; 2016; 4(2):239-256. PubMed ID: 28261653
[TBL] [Abstract][Full Text] [Related]
18. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib plus Trametinib in Pediatric Glioma with
Bouffet E; Hansford JR; Garrè ML; Hara J; Plant-Fox A; Aerts I; Locatelli F; van der Lugt J; Papusha L; Sahm F; Tabori U; Cohen KJ; Packer RJ; Witt O; Sandalic L; Bento Pereira da Silva A; Russo M; Hargrave DR
N Engl J Med; 2023 Sep; 389(12):1108-1120. PubMed ID: 37733309
[TBL] [Abstract][Full Text] [Related]
20. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]